



an Open Access Journal by MDPI

Nanomedicine with Neuroprotective Activity

Guest Editors:

Dr. Venkatesan Perumal

Center for Injury Biomechanics,
Materials and Medicine,
Department of Biomedical
Engineering, New Jersey Institute
of Technology, Newark, NJ 07102,
USA

Dr. Arun Reddy Ravula

Center for Injury Biomechanics,
Materials and Medicine,
Department of Biomedical
Engineering, New Jersey Institute
of Technology, Newark, NJ 07102,
USA

Dr. Agnieszka Agas

Center for Injury Biomechanics,
Materials and Medicine,
Department of Biomedical
Engineering, New Jersey Institute
of Technology, Newark, NJ 07102,
USA

Message from the Guest Editors

Neurodegenerative disease is a type of neurological disorder that alters brain functionality due to the progressive deterioration of neurons in different brain regions. The most common neurodegenerative diseases are AD and PD. Aging populations are the main target for these diseases as older people experience cognitive impairments, decrease in muscle control and motor coordination, impaired language, memory loss, and a reduction in quality of life. As stated by the World Health Organization, neurodegenerative disease will be the biggest health issue of the twenty-first century. However, there is no specific treatment to cure these diseases; rather, it is the symptoms which are treated. Conventional drug delivery methods cannot cross these barriers at a lower dosage, whereas a higher dosage can cause severe adverse neurotoxicity. Nanoparticle-based drug delivery systems not only amplify drugs' therapeutic effects but also mitigate toxicity that can be caused due to overdosage. This Special Issue intends to publish papers which focus on the recent advances in nanotechnology or nanoparticle-based drug delivery systems involved in treating neurodegenerative diseases.

Deadline for manuscript
submissions:

25 September 2024



mdpi.com/si/187459

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com